New evidence that bee venom therapy or api-puncture provides physiological benefits. This study confirms that the negative side effects of a chemotherapy drug used in treating colorectal cancer, which causes pain, numbness or hypersensitivity (neuropathy), is improved when bee venom therapy is applied. Even though bee venom may produce fear in some, it actually provides relief for many. From arthritis to multiple sclerosis and sports injuries to pain management, bee venom therapy has been documented to provide relief and improve conditions. Very positive news for many neuropathy victims...
Effect of bee venom acupuncture on oxaliplatin-induced cold allodynia in rats
Evid Based Complement Alternat Med, 2013, July
Oxaliplatin, a chemotherapy drug, often leads to neuropathic cold allodynia after a single administration. Bee venom acupuncture (BVA) has been used in Korea to relieve various pain symptoms and is shown to have a potent antiallodynic effect in nerve-injured rats.
We examined whether BVA relieves oxaliplatin-induced cold allodynia and which endogenous analgesic system is implicated. The cold allodynia induced by an oxaliplatin injection (6 mg/kg, i.p.) was evaluated by immersing the rat's tail into cold water (4°C) and measuring the withdrawal latency. BVA (1.0 mg/kg, s.c.)at Yaoyangguan (GV3), Quchi (LI11), or Zusanli (ST36) acupoints significantly reduced cold allodynia with the longest effect being shown in the GV3 group. Conversely, a high dose of BVA (2.5 mg/kg) at GV3 did not show a significant antiallodynic effect. Phentolamine ( α -adrenergic antagonist, 2 mg/kg, i.p.) partially blocked the relieving effect of BVA on allodynia, whereas naloxone (opioid antagonist, 2 mg/kg, i.p.) did not. We further confirmed that an intrathecal administration of idazoxan ( α 2-adrenergic antagonist, 50 μ g) blocked the BVA-induced anti-allodynic effect.
These results indicate that BVA alleviates oxaliplatin-induced cold allodynia in rats, at least partly, through activation of the noradrenergic system. Thus, BVA might be a potential therapeutic option in oxaliplatin-induced neuropathy.